{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-25-000043","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.712929+00:00","generated_at":"2026-05-17T04:44:48.023754+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AbbVie cuts FY 2025 adjusted EPS guidance to $10.38-$10.58 on $2.68B Q3 IPR&D charge","bullets":["Q3 2025 acquired IPR&D and milestones expense of $2.68B reduces adjusted EPS by $1.50.","Q3 2025 adjusted EPS guidance revised to $1.74-$1.78 from prior $3.24-$3.28.","Full-year 2025 adjusted EPS guidance lowered to $10.38-$10.58 from $11.88-$12.08.","Previously announced FY guidance excluded Q3 IPR&D; further IPR&D beyond Q3 not forecasted.","Q3 results not finalized; preliminary estimates subject to closing procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-25-000043","json":"https://secwatch.observer/filing/0001551152-25-000043.json","markdown":"https://secwatch.observer/filing/0001551152-25-000043.md","text":"https://secwatch.observer/filing/0001551152-25-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000043/0001551152-25-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000043/abbv-20251003.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:44:48.023754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}